Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 30;10(10):e1004459.
doi: 10.1371/journal.ppat.1004459. eCollection 2014 Oct.

Host Cofactors and Pharmacologic Ligands Share an Essential Interface in HIV-1 Capsid That Is Lost Upon Disassembly

Affiliations
Free PMC article

Host Cofactors and Pharmacologic Ligands Share an Essential Interface in HIV-1 Capsid That Is Lost Upon Disassembly

Amanda J Price et al. PLoS Pathog. .
Free PMC article

Abstract

The HIV-1 capsid is involved in all infectious steps from reverse transcription to integration site selection, and is the target of multiple host cell and pharmacologic ligands. However, structural studies have been limited to capsid monomers (CA), and the mechanistic basis for how these ligands influence infection is not well understood. Here we show that a multi-subunit interface formed exclusively within CA hexamers mediates binding to linear epitopes within cellular cofactors NUP153 and CPSF6, and is competed for by the antiretroviral compounds PF74 and BI-2. Each ligand is anchored via a shared phenylalanine-glycine (FG) motif to a pocket within the N-terminal domain of one monomer, and all but BI-2 also make essential interactions across the N-terminal domain: C-terminal domain (NTD:CTD) interface to a second monomer. Dissociation of hexamer into CA monomers prevents high affinity interaction with CPSF6 and PF74, and abolishes binding to NUP153. The second interface is conformationally dynamic, but binding of NUP153 or CPSF6 peptides is accommodated by only one conformation. NUP153 and CPSF6 have overlapping binding sites, but each makes unique CA interactions that, when mutated selectively, perturb cofactor dependency. These results reveal that multiple ligands share an overlapping interface in HIV-1 capsid that is lost upon viral disassembly.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Binding of HIV-1 hexamer to CPSF6, NUP153, PF74 and BI-2.
(A) ITC binding isotherms of HIV-1 hexamer titrated into different ligands in either the presence or absence of DTT. For both CPSF6 and NUP153, a peptide corresponding to residues 313–327 or 1407–1423 respectively was used. (B) Titration of HIV-1 cofactors CPSF6 and NUP153 into hexamer in the presence of pharmacologic inhibitors. Thermodynamic parameters are indicated for interactions displaying a clear binding isotherm; approximate affinities are shown for weak interactions; NB = no binding detectable.
Figure 2
Figure 2. Crystal structures of CPSF6313–327 (A) and NUP1531407–1423 (B) FG-containing peptides in complex with HIV-1 hexamer.
The P6 crystal form is shown, with the six subunits of the HIV-1 capsid generated by crystallographic symmetry. The capsid is shown in a ribbon representation with each monomer colored differently. Atoms comprising the cofactor peptides are shown as spheres, with each peptide colored separately. There are six cofactor binding sites per hexamer and six bound cofactor peptides. For each structure two views are shown, related by 90°.
Figure 3
Figure 3. CPSF6 and NUP153 bind a multi-subunit interface in HIV-1 hexamer.
(A) Two monomers from the CPSF6 P212121 complexed structure are shown in gray and teal, with the CPSF6 peptide in yellow and the NUP153 peptide from the P212121 complexed structure superposed and shown in pink. The helices that comprise the binding site are numbered. (B) Two monomers from the uncomplexed P212121 hexamer structure (3H4E) showing representative helices 8 and 9 in ‘open’ (teal) and ‘closed’ (green) states are superposed. The side-chain of residue Q179 is shown in stick representation. (C) CPSF6 binding site in the P212121 structure, with the peptide shown in yellow and subunits colored as above. (D) NUP153 binding site in the P212121 structure, with peptide shown in pink and subunits colored as above. CPSF6 and NUP153 preferentially bind an open conformation of helices 8 and 9.
Figure 4
Figure 4. CPSF6 and NUP153 interact with distinct sets of CA residues within the hexamer interface.
A molecular surface representation of the CPSF6 and NUP153 binding site in hexameric capsid is shown in gray. The interface is formed between two neighbouring monomers and is shown in a similar orientation to Figure 3. The CPSF6 (A) and NUP153 (B) peptides in the different complexed structures are shown in yellow and pink respectively. The binding ‘footprint’ of each ligand is shown in red for CPSF6 and yellow for NUP153. The footprint was calculated using PISA and is defined as residues containing atoms that become desolvated upon binding (i.e. are within 1.4 Å of the ligand).
Figure 5
Figure 5. CPSF6 and NUP153 interact both within and between CA monomers.
Detailed views of the interactions between the ligands and the binding site within hexameric capsid are shown. In each case two adjacent monomers of the hexamer are colored gray and teal, with the side chains of specific contacting residues displayed and labelled in standard text. Potential hydrogen bonds with ligands are indicated by dashed lines. The upper panels (A and B) focus on interactions that occur in the first binding site (within one monomer), while the lower panels (C and D), show interactions in the second binding site (with the second monomer). CPSF6 is shown in yellow and NUP153 in pink, with important ligand residues labelled in bold and italic text.
Figure 6
Figure 6. Sensitivity of CA mutants to restriction by CPSF6ΔNLS or TRIM-NUP153 or depletion of TNPO3.
Titres of VSV-G pseudotyped GFP-encoding HIV-1 vectors bearing wild type or mutant CA on HeLa cells expressing empty vector (EV) or CPSF6ΔNLS (A), control knockdown cells (shControl) or cells depleted of TNPO3 (shTNPO3) (B), control knockdown cells (shControl) or cells expressing empty vector (EV) or TRIM-NUP153 (C). In each case infectivity is plotted as infectious units (IU)/ng p24. The data are representative of two independent experiments, each using three different virus doses.
Figure 7
Figure 7. HIV-1 CA hexamer complexes with pharmacologic ligands BI-2 and PF74.
Two monomers from hexameric structures complexed with BI-2 (A) and PF74 (B) are shown in a close-up view of the binding site, with one monomer in gray and a second monomer in teal. BI-2 is shown in orange and PF74 in green. Important CA interacting residues are shown as sticks and putative hydrogen bonds indicated by dashed lines. Ligplots are shown for BI-2 (C) and PF74 (D) in which a ball-and-stick representation of the ligand is shown together with CA residues that contribute a hydrogen bond. Other interacting CA residues are indicated with a red-dashed semi-circle. Circled areas indicate interacting CA residues that are shared between both structures. (E) Superposition of the BI-2:hexamer complex (BI-2 in orange) with the previously solved BI-1:CA-NTD complex (BI-1 in blue). The secondary structure of the superposed monomers from each structure is shown in gray, while capsid side-chains from only the hexamer complex are depicted. The adjacent monomer in the hexamer complex is shown in teal. (F) Superposition of the PF74:hexamer complex (PF74 in green) with the previously solved PF74:CA-NTD complex (PF74 in slate). The capsids are colored as in (E).
Figure 8
Figure 8. Structures of PF74 derivatives used in this study and their affinities of binding to CA.
Affinities of binding to hexamer as measured by ITC are shown. No binding was detected between PF74_1 and PF74_2 to HIV-1 CA NTD, therefore the interaction with hexamer was not tested.
Figure 9
Figure 9. Inhibition of HIV-1 infection by BI-2, PF74 and PF74 derivatives.
(A) Titration of PF74 or indicated derivatives onto HeLa cells infected with VSV-G pseudotyped GFP-encoding HIV-1 vector. For each titration, infectivity is normalised to the level in the absence of inhibitor (100%). (B) Correlation between the IC90 values derived from (A) and the Kd values for purified hexameric capsid as calculated by ITC (Figure 8). The values are highly correlative with a Pearson correlation coefficient of 0.9928 and a P-value of 0.0007. (C) Titration of PF74 or BI-2 onto cells infected with VSV-G pseudotyped GFP-encoding HIV-1 vectors, normalized as in (A). (D) Data from (C) but with infectivity plotted against drug concentration divided by affinity to hexamer as calculated by ITC. (E) Titres of VSV-G pseudotyped GFP-encoding HIV-1 vectors 48 h post-infection and levels of reverse transcription (RT) 4 h post-infection under conditions of PF74 inhibition. For both measures, data are normalized to the values obtained in the absence of inhibitor. (F) Data from (E), except plotted against the calculated level of CA occupancy by PF74. The occupancy was calculated assuming that there are 1500 free sites per capsid and that number of free sites = 1500(1−([PF74]/Kd[PF74])) (G) Infectivity and reverse transcription in cells infected in the presence of PF74 (wash) or when removed after four hours (wash out). Reverse transcription was then measured after a further 4 h, while infectivity was determined 48 h post-infection. (H) Levels of reverse transcription 4 h post-infection of HeLa cells in the presence of PF74 and its derivatives at 20× IC9o drug concentrations.

Similar articles

See all similar articles

Cited by 81 articles

See all "Cited by" articles

References

    1. Franke EK, Yuan HE, Luban J (1994) Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372: 359–362. - PubMed
    1. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, et al. (2010) Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7: 221–233. - PMC - PubMed
    1. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, et al. (2013) HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 503: 402–405. - PMC - PubMed
    1. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921–926. - PubMed
    1. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, et al. (2009) Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog 5: e1000437. - PMC - PubMed

Publication types

MeSH terms

Feedback